Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
Open Access
- 4 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 65 (6), 1571-1575
- https://doi.org/10.1007/s10620-020-06299-y
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Detection of SARS-CoV-2 in Different Types of Clinical SpecimensJAMA, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- [Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].2020
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Gut, 2019
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Emerging immunological targets in inflammatory bowel diseaseCurrent Opinion in Pharmacology, 2011
- Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transportersPharmacology & Therapeutics, 2010